Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Horizon Therapeutics plc

< Previous 1 2 3 4 5 6 Next >
Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab (HZN-7734) for the Treatment of Alopecia Areata
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc Ranked Second in Overall Corporate Reputation in U.S. PatientView Survey of Patient Groups
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc Announces Dara Mann as a Healthcare Businesswomen’s Association 2022 Rising Star
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc Launches Letter-Writing Campaign to Empower Those Living with Thyroid Eye Disease (TED) to Confront the Condition Head On
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc Reports First-Quarter 2022 Financial Results
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Topline Data for Dazodalibep (HZN-4920) Meets Primary Endpoint in Rheumatoid Arthritis
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc Launches #RAREis Global Advocate Grant Program to Support the Rare Disease Community
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc Receives European Commission (EC) Approval of UPLIZNA® (inebilizumab) for the Treatment of Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD)
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc Among Top Companies for Overall Corporate Reputation in 2021 Global PatientView Survey of Patient Groups Worldwide
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics and Massachusetts Institute of Technology (MIT) Solve Announce Second Annual Horizon Prize to Inspire Solutions that Improve the Quality of Life for the Global Rare Disease Community
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc to Release First-Quarter 2022 Financial Results and Host Webcast on May 4, 2022
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc Named One of the Fortune 100 Best Companies to Work For®
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
New Analysis Finds UPLIZNA® (inebilizumab-cdon) Effective for People with Newly-Presenting Neuromyelitis Optica Spectrum Disorder (NMOSD)
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc Named as One of the Best Workplaces in Ireland
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc Launches #RAREis Representation Program to Elevate Global Rare Disease Equity
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc Initiates Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating Teprotumumab for the Treatment of Active Thyroid Eye Disease (TED)
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc to Present at the Cowen and Company 42nd Annual Health Care Conference
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc Names Sean Clayton Executive Vice President and General Counsel
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
New Analysis Demonstrates UPLIZNA® (inebilizumab-cdon) Reduces Severity of Attacks Associated with Neuromyelitis Optica Spectrum Disorder (NMOSD)
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
New Post-Marketing Safety Analysis Shows Rate of Hearing-Related Events Associated with TEPEZZA® (teprotumumab-trbw) Comparable with Clinical Trial Observations
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc Partners with the Doug the Pug Foundation and Sing Me A Story Foundation to Bring Awareness to Rare Diseases Impacting Children through #RAREis Playlist
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc Named Title Partner of the Irish Open
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc to Release Fourth-Quarter and Full-Year 2021 Financial Results and Host Webcast on March 1, 2022
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2b Pivotal Trial Evaluating HZN-825 for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc Submits Supplemental Biologics License for the Concomitant Use of KRYSTEXXA® (pegloticase injection) Plus Methotrexate for People Living with Uncontrolled Gout
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc Announces Significant Expansion of East Coast Research and Development and Technical Operations Capability
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc to Participate in Upcoming Investor Conferences
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc Makes $100,000 Seed Donation to Support Fundraising Efforts to Renovate Emmett Till’s Home into a Museum and Theater
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Great Place to Work Names Horizon Therapeutics plc to Best Workplaces for Parents List
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc Provides Academic Scholarships to Help Economically Disadvantaged Students in Ireland Further Their STEM Education
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.